Chemomab Therapeutics Ltd.
Recent Filings
All 336 filings →| Form | Description | Date |
|---|---|---|
| 20-F | 20-F | Mar 23, 2026 |
| 6-K | 6-K | Mar 20, 2026 |
| 6-K | 6-K | Mar 19, 2026 |
| SCHEDULE 13G/A | — | Feb 17, 2026 |
| SCHEDULE 13G/A | — | Feb 10, 2026 |
| 6-K | 6-K | Nov 21, 2025 |
| 6-K | 6-K | Aug 22, 2025 |
| 6-K | 6-K | Aug 14, 2025 |
| SCHEDULE 13G/A | — | Aug 11, 2025 |
| 6-K | 6-K | Jul 25, 2025 |
Insider Transactions
View all →| Insider | Title | Type | Shares | Owns After | Date |
|---|---|---|---|---|---|
| OrbiMed Israel BioFund GP Limited Partnership | — | Sale | 266,376 @ $3.34 | 2,311,798 | Jan 3, 2023 |
| Mor George Adi | Chief Scientific Officer | Sale | 7,700 @ $5.03 | 317,075 | Jan 3, 2023 |
| Cohen Neil Harris | — | Sale | 2,409 @ $2.00 | 10,000 | Nov 16, 2022 |
| Mor George Adi | Chief Scientific Officer | Sale | 257,248 @ $2.08 | 257,247 | Nov 16, 2022 |
| Maryles Joel Michael | — | Purchase | 33 @ $2.76 | 1,433 | May 24, 2022 |
| Cohen Neil Harris | — | Purchase | 2,000 @ $3.19 | 12,409 | May 18, 2022 |
| Maryles Joel Michael | — | Purchase | 500 @ $4.32 | 500 | Mar 18, 2022 |
| Marvin Donald | Executive VP, CFO & COO | Purchase | 250 @ $3.25 | 2,000 | Mar 16, 2022 |
| Marvin Donald | Executive VP, CFO & COO | Purchase | 250 @ $3.98 | 500 | Mar 14, 2022 |
| Pfost Dale R | Chief Executive Officer | Purchase | 1,800 @ $3.98 | 1,800 | Mar 14, 2022 |